- Home
- KPRX vs SLXN Comparison
KPRX vs SLXN Comparison
Compare KPRX & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- SLXN
- Stock Information
- Founded
- KPRX 1998
- SLXN 2008
- Country
- KPRX United States
- SLXN Israel
- Employees
- KPRX N/A
- SLXN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SLXN
- Sector
- KPRX Health Care
- SLXN
- Exchange
- KPRX Nasdaq
- SLXN NYSE
- Market Cap
- KPRX 9.1M
- SLXN 7.3M
- IPO Year
- KPRX N/A
- SLXN N/A
- Fundamental
- Price
- KPRX $2.82
- SLXN $0.80
- Analyst Decision
- KPRX Strong Buy
- SLXN Strong Buy
- Analyst Count
- KPRX 1
- SLXN 1
- Target Price
- KPRX $10.00
- SLXN $5.00
- AVG Volume (30 Days)
- KPRX 1.4M
- SLXN 151.3K
- Earning Date
- KPRX 08-08-2025
- SLXN 08-21-2025
- Dividend Yield
- KPRX N/A
- SLXN N/A
- EPS Growth
- KPRX N/A
- SLXN N/A
- EPS
- KPRX N/A
- SLXN N/A
- Revenue
- KPRX $20,000.00
- SLXN N/A
- Revenue This Year
- KPRX N/A
- SLXN N/A
- Revenue Next Year
- KPRX N/A
- SLXN N/A
- P/E Ratio
- KPRX N/A
- SLXN N/A
- Revenue Growth
- KPRX N/A
- SLXN N/A
- 52 Week Low
- KPRX $2.51
- SLXN $0.58
- 52 Week High
- KPRX $4.86
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- KPRX 40.86
- SLXN N/A
- Support Level
- KPRX $2.87
- SLXN N/A
- Resistance Level
- KPRX $3.22
- SLXN N/A
- Average True Range (ATR)
- KPRX 0.18
- SLXN 0.00
- MACD
- KPRX -0.03
- SLXN 0.00
- Stochastic Oscillator
- KPRX 21.20
- SLXN 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.